	Application No.	Applicant(s)
Notice of Allowability	10/768,769 Examiner	PERRICONE, NICHOLAS V.  Art Unit
	Vickie Kim	1618
The MAILING DATE of this communication appeal All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIOF of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this ap or other appropriate communication IGHTS. This application is subject to	plication. If not included will be mailed in due course. THIS
1. $\boxtimes$ This communication is responsive to <u>examiner's amendment</u>	nt requested on 3/16/06.	
2. The allowed claim(s) is/are <u>1,3-6,8-12,14 and 15</u> .		
<ul> <li>3. Acknowledgment is made of a claim for foreign priority una)</li> <li>All b) Some* c) None of the:</li> <li>1. Certified copies of the priority documents have</li> <li>2. Certified copies of the priority documents have</li> <li>3. Copies of the certified copies of the priority documents have</li> <li>International Bureau (PCT Rule 17.2(a)).</li> <li>* Certified copies not received:</li> </ul>	been received. been received in Application No	
Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONM THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.	of this communication to file a reply IENT of this application.	complying with the requirements
4. A SUBSTITUTE OATH OR DECLARATION must be subm INFORMAL PATENT APPLICATION (PTO-152) which give		
<ul> <li>5. ☐ CORRECTED DRAWINGS ( as "replacement sheets") must</li> <li>(a) ☐ including changes required by the Notice of Draftspers</li> <li>1) ☐ hereto or 2) ☐ to Paper No./Mail Date</li> <li>(b) ☐ including changes required by the attached Examiner's Paper No./Mail Date</li> <li>Identifying indicia such as the application number (see 37 CFR 1 each sheet. Replacement sheet(s) should be labeled as such in the deposition of the deposition of</li></ul>	on's Patent Drawing Review (PTO s Amendment / Comment or in the C .84(c)) should be written on the drawing to 37 CFR 1.121(	Office action of ngs in the front (not the back) of d).
attached Examiner's comment regarding REQUIREMENT	FOR THE DEPOSIT OF BIOLOGIC.	AL MATERIAL.
Attachment(s) 1. ☐ Notice of References Cited (PTO-892)	E  Notice of Informal D	lotopt Application (DTO 450)
2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)	6. ☐ Interview Summary Paper No./Mail Dat	
<ol> <li>Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date</li> </ol>	8), 7. Examiner's Amendr	
Examiner's Comment Regarding Requirement for Deposit of Biological Material	8.  Examiner's Stateme	ent of Reasons for Allowance
	VIEKIE KIM	

Application/Control Number: 10/768,769

Art Unit: 1618

## **EXAMINER'S AMENDMENT**

Page 2

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Ms. Helen M. Limoncelli(Applicant's Rep) on 3/15/06.

The application has been amended as follows:

- a. In claim 1, line 1 and line 16, delete [or preventing] and [or prevent] right before "acne", respectively.
- b. In claim 1, line 2 and 14, delete [, or susceptile to,] right after "affected by", and delete [and] right after "thereof;", respectively.
- c. In claim 1, line 15, insert ---; and optionally, an adjunct ingredient selected from the group consisting an α-hydroxy acid, a fatty acid ester of ascorbic acid, and mixtures of any of these---- between "carrier" and ",wherein".
- d. In claims 5-6, line 1, replace [contains] with --consists of-- right after "composition", respectively.
- e. Cancel claim 7 and 13.
- f. In claim 8, line 1, replace [claim 7 wherein the conventional acne

..

Application/Control Number: 10/768,769

**Art Unit: 1618** 

medication] with ---claim 1 wherein a conventional acne medication --- right after "according to".

- g. In claims 9-11, line 1, delete [the active ingredient in] right after "wherein", respectively.
- h. In claim 12, replace [claim 7 wherein the conventional acne medication]
  with ---claim 1 wherein a conventional acne medication --- right after
  "according to".
- i. In claim 14, lines 1-2, replace [claim 13 wherein the composition contains] with --- claim 1 wherein  $\alpha$ -hydroxy acid is --- right after "according to".
- j. In claim 15, lines 1-2, replace [claim 13 wherein the composition contains] with --- claim 1 wherein a fatty acid ester of ascorbic acid is --- right after "according to".

## Conclusion

- 1. All the pending claims 1, 3-6, 8-12, and 14-15 are allowed.
- Any inquiry concerning this communication or earlier communications from the examiner should be directed to Vickie Kim whose telephone number is 571-272-0579.
   The examiner can normally be reached on Tuesday-Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Hartley be reached on 571-272-0616. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for

published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only.

For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

VICKIE KIM PRIMARY EXAMINER

Vickie Kim March 17, 2006 Art unit 1618